{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:24:51Z","timestamp":1788272691691,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.drudis.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:25:59Z","timestamp":1649193959000},"page":"1994-2007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases"],"prefix":"10.1016","volume":"27","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.04.003_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2022.04.003_b0010","article-title":"Old drugs as new treatments for neurodegenerative diseases","volume":"11","author":"Duraes","year":"2018","journal-title":"Pharm (Basel)"},{"key":"10.1016\/j.drudis.2022.04.003_b0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2022.04.003_b0020","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2022.04.003_b0025","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.drudis.2022.04.003_b0030","article-title":"Autophagy and neurodegenerative diseases","volume":"9","author":"Watanabe","year":"2020","journal-title":"Cells-Basel"},{"key":"10.1016\/j.drudis.2022.04.003_b0035","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2022.04.003_b0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.04.003_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112275","article-title":"A medicinal chemistry perspective of drug repositioning: recent advances and challenges in drug discovery","volume":"195","author":"Pillaiyar","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2022.04.003_b0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","article-title":"Drug repositioning and repurposing for Alzheimer disease","volume":"16","author":"Ballard","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2022.04.003_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/alz.12175","article-title":"Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: a scoping review","volume":"17","author":"Thunell","year":"2021","journal-title":"Alzheimers Dementia"},{"key":"10.1016\/j.drudis.2022.04.003_b0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijbiomac.2020.11.192","article-title":"Review on Alzheimer's disease: inhibition of amyloid beta and tau tangle formation","volume":"167","author":"Ashrafian","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2022.04.003_b0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1741-7015-11-82","article-title":"Potential repurposing of oncology drugs for the treatment of Alzheimer's disease","volume":"11","author":"Araki","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.drudis.2022.04.003_b0070","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/17425255.2020.1811232","article-title":"Retinoic acid receptor-targeted drugs in neurodegenerative disease","volume":"16","author":"Clark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.drudis.2022.04.003_b0075","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.gendis.2020.11.008","article-title":"Sulfuretin exerts diversified functions in the processing of amyloid precursor protein","volume":"8","author":"Chen","year":"2021","journal-title":"Genes Dis"},{"key":"10.1016\/j.drudis.2022.04.003_b0080","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41598-018-19577-7","article-title":"Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks","volume":"8","author":"Reinhardt","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.04.003_b0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737175.2020.1708195","article-title":"Antihypertensive agents in Alzheimer's disease: beyond vascular protection","volume":"20","author":"Lebouvier","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.drudis.2022.04.003_b0090","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnagi.2018.00164","article-title":"The role of fluoxetine in activating Wnt\/beta-catenin signaling and repressing beta-amyloid production in an Alzheimer mouse model","volume":"10","author":"Huang","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.drudis.2022.04.003_b0095","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1021\/acs.biomac.0c01802","article-title":"Attenuation of human lysozyme amyloid fibrillation by ACE inhibitor captopril: a combined spectroscopy, microscopy, cytotoxicity, and docking study","volume":"22","author":"Jin","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.drudis.2022.04.003_b0100","doi-asserted-by":"crossref","first-page":"110887","DOI":"10.1016\/j.biopha.2020.110887","article-title":"Melatonin regulates Abeta production\/clearance balance and Abeta neurotoxicity: a potential therapeutic molecule for Alzheimer's disease","volume":"132","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2022.04.003_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00062","article-title":"Valproic acid stimulates hippocampal neurogenesis via activating the Wnt\/beta-catenin signaling pathway in the APP\/PS1\/Nestin-GFP triple transgenic mouse model of Alzheimer's disease","volume":"11","author":"Zeng","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.drudis.2022.04.003_b0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature09325","article-title":"Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease","volume":"467","author":"He","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.04.003_b0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/pcn.12637","article-title":"Therapeutic role of rifampicin in Alzheimer's disease","volume":"72","author":"Yulug","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.drudis.2022.04.003_b0120","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12759","article-title":"Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice","volume":"17","author":"Giannopoulos","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.drudis.2022.04.003_b0125","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1021\/acs.biomac.1c00344","article-title":"Evidence of anti-amyloid characteristics of plumbagin via inhibition of protein aggregation and disassembly of protein fibrils","volume":"22","author":"Anand","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.drudis.2022.04.003_b0130","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1080\/07391102.2018.1511475","article-title":"Insights into the inhibitory mechanism of a resveratrol and clioquinol hybrid against A beta(42) aggregation and protofibril destabilization: a molecular dynamics simulation study","volume":"37","author":"Saini","year":"2019","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.drudis.2022.04.003_b0135","doi-asserted-by":"crossref","first-page":"635760","DOI":"10.3389\/fnagi.2021.635760","article-title":"Doxycycline interferes with Tau aggregation and reduces its neuronal toxicity","volume":"13","author":"Medina","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.drudis.2022.04.003_b0140","doi-asserted-by":"crossref","first-page":"20258","DOI":"10.1038\/s41598-020-76927-0","article-title":"CMT-3 targets different alpha-synuclein aggregates mitigating their toxic and inflammogenic effects","volume":"10","author":"Gonzalez-Lizarraga","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.04.003_b0145","article-title":"The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress","volume":"10","author":"Ferreira Junior","year":"2021","journal-title":"Cells-Basel"},{"key":"10.1016\/j.drudis.2022.04.003_b0150","article-title":"Resveratrol, metabolic dysregulation, and Alzheimer's disease: considerations for neurogenerative disease","volume":"22","author":"Yang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2022.04.003_b0155","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1007\/s12035-020-01969-4","article-title":"Naringenin upregulates AMPK-mediated autophagy to rescue neuronal cells from beta-amyloid (1\u201342) evoked neurotoxicity","volume":"57","author":"Ahsan","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.drudis.2022.04.003_b0160","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/15548627.2021.1909409","article-title":"Targeting autophagy as a therapeutic strategy to prevent dopamine neuron loss in early stages of Alzheimer disease","volume":"17","author":"Nobili","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.drudis.2022.04.003_b0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.exger.2017.02.004","article-title":"Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of beta-amyloid in APP\/tau\/PS1 mouse model of Alzheimer's disease","volume":"91","author":"Huang","year":"2017","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.drudis.2022.04.003_b0170","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.04.003_b0175","doi-asserted-by":"crossref","first-page":"e1501244","DOI":"10.1126\/sciadv.1501244","article-title":"An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A\u03b242 aggregates linked with Alzheimer's disease","volume":"2","author":"Habchi","year":"2016","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2022.04.003_b0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trsl.2017.11.004","article-title":"Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline","volume":"193","author":"Schaler","year":"2018","journal-title":"Transl Res"},{"key":"10.1016\/j.drudis.2022.04.003_b0185","article-title":"Diagnosis and treatment of Parkinson disease","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2022.04.003_b0190","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2022.04.003_b0195","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2022.04.003_b0200","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.drudis.2022.04.003_b0205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nbd.2017.07.007","article-title":"Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form","volume":"106","author":"Collier","year":"2017","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2022.04.003_b0210","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2022.04.003_b0215","unstructured":"Sanders HM, Jovcevski B, Marty MT, Pukala TL. Structural and mechanistic insights into amyloid-beta and alpha-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers. Febs J."},{"key":"10.1016\/j.drudis.2022.04.003_b0220","doi-asserted-by":"crossref","first-page":"41755","DOI":"10.1038\/srep41755","article-title":"Repurposing doxycycline for synucleinopathies: remodelling of alpha-synuclein oligomers towards non-toxic parallel beta-sheet structured species","volume":"7","author":"Gonzalez-Lizarraga","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.04.003_b0225","doi-asserted-by":"crossref","first-page":"105256","DOI":"10.1016\/j.nbd.2021.105256","article-title":"Doxycycline inhibits alpha-synuclein-associated pathologies in vitro and in vivo","volume":"151","author":"Dominguez-Meijide","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2022.04.003_b0230","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"Jama Neurol"},{"key":"10.1016\/j.drudis.2022.04.003_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110968","article-title":"Traditional Chinese medicine compounds regulate autophagy for treating neurodegenerative disease: a mechanism review","volume":"133","author":"Wang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2022.04.003_b0240","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/s41467-019-09494-2","article-title":"Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing","volume":"10","author":"Siddiqi","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.04.003_b0245","article-title":"Antioxidant and anti-inflammatory effect of Nrf2 inducer dimethyl fumarate in neurodegenerative diseases","volume":"9","author":"Scuderi","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.drudis.2022.04.003_b0250","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/mds.28072","article-title":"Precision medicine for Parkinson's disease: ambroxol for glucocerebrosidase-associated Parkinson's disease, first trial completed","volume":"35","author":"Schneider","year":"2020","journal-title":"Mov Disord"},{"key":"10.1016\/j.drudis.2022.04.003_b0255","doi-asserted-by":"crossref","first-page":"153578","DOI":"10.1016\/j.phymed.2021.153578","article-title":"Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models","volume":"87","author":"Zhu","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.drudis.2022.04.003_b0260","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","article-title":"Improving clinical trial outcomes in amyotrophic lateral sclerosis","volume":"17","author":"Kiernan","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2022.04.003_b0265","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.sbi.2020.12.002","article-title":"SOD1 oligomers in amyotrophic lateral sclerosis","volume":"66","author":"Choi","year":"2021","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.drudis.2022.04.003_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS Genetics, mechanisms, and therapeutics: where are we now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.drudis.2022.04.003_b0275","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/cns.12855","article-title":"Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1-G93A mouse model","volume":"24","author":"Zhang","year":"2018","journal-title":"Cns Neurosci Ther"},{"key":"10.1016\/j.drudis.2022.04.003_b0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis","volume":"9","author":"Imamura","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.04.003_b0285","doi-asserted-by":"crossref","first-page":"e0210752","DOI":"10.1371\/journal.pone.0210752","article-title":"Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS","volume":"14","author":"Rando","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.04.003_b0290","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-0826-3","article-title":"Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy","volume":"3","author":"Chantadul","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2022.04.003_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105515","article-title":"Thioridazine reverts the phenotype in cellular and Drosophila models of amyotrophic lateral sclerosis by enhancing TDP-43 aggregate clearance","volume":"160","author":"Cragnaz","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2022.04.003_b0300","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2022.04.003_b0305","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrd.2018.133","article-title":"Therapeutic approaches to Huntington disease: from the bench to the clinic","volume":"17","author":"Caron","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.drudis.2022.04.003_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10010043","article-title":"Therapeutic advances for Huntington's disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Brain Sci"},{"key":"10.1016\/j.drudis.2022.04.003_b0315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bcp.2019.07.002","article-title":"Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate","volume":"168","author":"Weber","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2022.04.003_b0320","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s11011-019-00405-4","article-title":"Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington's disease patients","volume":"34","author":"Pierzynowska","year":"2019","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.drudis.2022.04.003_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197174","article-title":"Melatonin and autophagy in aging-related neurodegenerative diseases","volume":"21","author":"Luo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2022.04.003_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122109","article-title":"Posiphen reduces the levels of huntingtin protein through translation suppression","volume":"13","author":"Chen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2022.04.003_b0335","doi-asserted-by":"crossref","first-page":"e1801362","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood\u2013brain barrier: the role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv Mater"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:50Z","timestamp":1761224450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1359644622001349"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.04.003","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}